HIGHLIGHTS
- who: Takayuki Matsumae and colleagues from the Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA have published the paper: Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy, in the Journal: (JOURNAL)
- what: The authors showed for the first time that the prognosis of u-HCC patients treated with Atezo/Bev therapy was clearly stratified based on TERT ctDNA mutation and AFP level , suggesting the usefulness of ctDNA profiling as a prognostic biomarker . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.